S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.76 (+0.82%)
MSFT   212.77 (+1.16%)
FB   266.90 (+1.91%)
GOOGL   1,492.83 (+1.86%)
AMZN   3,202.68 (+1.71%)
TSLA   439.56 (+2.46%)
NVDA   543.24 (+0.37%)
BABA   291.27 (-0.92%)
CGC   14.23 (-0.63%)
MU   47.64 (+1.45%)
GE   6.16 (-1.12%)
AMD   83.69 (+2.07%)
T   28.56 (+0.18%)
F   6.73 (+1.05%)
ACB   4.69 (+0.86%)
GILD   62.86 (-0.52%)
NFLX   509.20 (+1.83%)
DIS   124.26 (+0.15%)
BA   169.20 (+2.38%)
BAC   24.12 (+0.12%)
S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.76 (+0.82%)
MSFT   212.77 (+1.16%)
FB   266.90 (+1.91%)
GOOGL   1,492.83 (+1.86%)
AMZN   3,202.68 (+1.71%)
TSLA   439.56 (+2.46%)
NVDA   543.24 (+0.37%)
BABA   291.27 (-0.92%)
CGC   14.23 (-0.63%)
MU   47.64 (+1.45%)
GE   6.16 (-1.12%)
AMD   83.69 (+2.07%)
T   28.56 (+0.18%)
F   6.73 (+1.05%)
ACB   4.69 (+0.86%)
GILD   62.86 (-0.52%)
NFLX   509.20 (+1.83%)
DIS   124.26 (+0.15%)
BA   169.20 (+2.38%)
BAC   24.12 (+0.12%)
S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.76 (+0.82%)
MSFT   212.77 (+1.16%)
FB   266.90 (+1.91%)
GOOGL   1,492.83 (+1.86%)
AMZN   3,202.68 (+1.71%)
TSLA   439.56 (+2.46%)
NVDA   543.24 (+0.37%)
BABA   291.27 (-0.92%)
CGC   14.23 (-0.63%)
MU   47.64 (+1.45%)
GE   6.16 (-1.12%)
AMD   83.69 (+2.07%)
T   28.56 (+0.18%)
F   6.73 (+1.05%)
ACB   4.69 (+0.86%)
GILD   62.86 (-0.52%)
NFLX   509.20 (+1.83%)
DIS   124.26 (+0.15%)
BA   169.20 (+2.38%)
BAC   24.12 (+0.12%)
S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.76 (+0.82%)
MSFT   212.77 (+1.16%)
FB   266.90 (+1.91%)
GOOGL   1,492.83 (+1.86%)
AMZN   3,202.68 (+1.71%)
TSLA   439.56 (+2.46%)
NVDA   543.24 (+0.37%)
BABA   291.27 (-0.92%)
CGC   14.23 (-0.63%)
MU   47.64 (+1.45%)
GE   6.16 (-1.12%)
AMD   83.69 (+2.07%)
T   28.56 (+0.18%)
F   6.73 (+1.05%)
ACB   4.69 (+0.86%)
GILD   62.86 (-0.52%)
NFLX   509.20 (+1.83%)
DIS   124.26 (+0.15%)
BA   169.20 (+2.38%)
BAC   24.12 (+0.12%)
Log in
NYSE:NVTA

InVitae Stock Forecast, Price & News

$44.26
+0.91 (+2.10 %)
(As of 10/1/2020 11:35 AM ET)
Add
Compare
Today's Range
$43.53
Now: $44.26▼
$44.63
50-Day Range
$29.01
MA: $35.58▼
$44.67
52-Week Range
$7.41
Now: $44.26▼
$46.17
Volume30,617 shs
Average Volume3.11 million shs
Market Capitalization$5.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.26
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Read More
InVitae logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.09 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:NVTA
Previous Symbol
CUSIPN/A
CIK1501134
Webwww.invitae.com
Phone415-374-7782

Debt

Debt-to-Equity Ratio0.69
Current Ratio3.71
Quick Ratio3.71

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$216.82 million
Price / Sales26.90
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.93 per share
Price / Book11.26

Profitability

EPS (Most Recent Fiscal Year)($2.28)
Net Income$-241,960,000.00
Net Margins-182.73%
Return on Equity-77.82%
Return on Assets-36.75%

Miscellaneous

Employees1,300
Outstanding Shares131,785,000
Market Cap$5.83 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$44.26
+0.91 (+2.10 %)
(As of 10/1/2020 11:35 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











InVitae (NYSE:NVTA) Frequently Asked Questions

How has InVitae's stock been impacted by COVID-19?

InVitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVTA shares have increased by 179.4% and is now trading at $44.28.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of InVitae?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InVitae.

When is InVitae's next earnings date?

InVitae is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for InVitae.

How were InVitae's earnings last quarter?

InVitae Corp (NYSE:NVTA) posted its quarterly earnings data on Tuesday, August, 4th. The medical research company reported ($0.77) EPS for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.15. The medical research company earned $46.20 million during the quarter, compared to analyst estimates of $39.63 million. InVitae had a negative return on equity of 77.82% and a negative net margin of 182.73%. InVitae's revenue for the quarter was down 14.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.54) EPS.
View InVitae's earnings history.

What price target have analysts set for NVTA?

6 brokers have issued 1-year price objectives for InVitae's stock. Their forecasts range from $20.00 to $38.00. On average, they anticipate InVitae's stock price to reach $33.54 in the next twelve months. This suggests that the stock has a possible downside of 24.3%.
View analysts' price targets for InVitae.

Who are some of InVitae's key competitors?

Some companies that are related to InVitae include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Guardant Health (GH), Natera (NTRA), ELEKTA AB/ADR (EKTAY), Burning Rock Biotech (BNR), CareDx (CDNA), Veracyte (VCYT), Genetron (GTH), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), RadNet (RDNT), Personalis (PSNL), ALX Oncology (RNLX) and Progenity (PROG).
View all competitors.

What other stocks do shareholders of InVitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), salesforce.com (CRM), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Tesla (TSLA), Advanced Micro Devices (AMD) and Walt Disney (DIS).

Who are InVitae's key executives?

InVitae's management team includes the following people:
  • Dr. Randal W. Scott, Exec. Chairman (Age 61)
  • Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 45)
  • Ms. Shelly D. Guyer, Chief Financial Officer (Age 59)
  • Mr. Lee Bendekgey, Sec. & COO (Age 61)
  • Ms. Laura D'Angelo, Head of Investor Relations

When did InVitae IPO?

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is InVitae's stock symbol?

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

How do I buy shares of InVitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is InVitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $44.28.

How big of a company is InVitae?

InVitae has a market capitalization of $5.84 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

What is InVitae's official website?

The official website for InVitae is www.invitae.com.

How can I contact InVitae?

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.